Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities
LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company's broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs' lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5).
The venture debt financing agreement is supported under the European Commission's InvestEU programme and specifically falls under 'HERA Invest.' This €110 million initiative from the European Health Union is meant to address biodefence, pandemic readiness and antimicrobial resistance in Europe, as a top-up to the European Union's InvestEU initiative, funded by the EU4Health programme.
'The COVID-19 pandemic taught us multiple lessons, including that we should strengthen the EU's preparedness and autonomy in key areas like bio sciences,' stated EIB Vice President Robert de Groot. 'With the support of the European Commission, the EIB backs highly innovative EU companies like Leyden Labs with venture debt, enabling them to grow and thrive in Europe. Technological innovations from companies like Leyden Labs are key for European competitiveness and the well-being of our society.'
Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, added: 'Respiratory viruses are common and affect us all, especially the most medically vulnerable. Today's agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.'
'We are thrilled with this endorsement of our approach and support from HERA and the European Investment Bank. This will accelerate our efforts to provide broad, universal protection against current and future viral outbreaks. We are grateful that HERA and the EIB understand the urgency and significance of investing in initiatives to ensure Europe is prepared for pandemic viruses. This concern is greater than ever given the increasing threat of an avian influenza outbreak,' said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs.
Leyden Labs' product candidates are nasal sprays that administer broadly protective antibodies directly to the respiratory mucosa. Leyden Lab's solutions are designed to work at the earliest moment, before the virus even reaches systemic circulation. Systemically administered vaccines primarily generate systemic protection against viruses, however, this may be a limitation that contributes to suboptimal efficacy. Airborne viruses, including influenza, do not directly enter systemic circulation, but rather, they enter the body through the nose and mouth. The Company's antibodies aim to protect against full viral families, so they keep working even when a virus mutates and evolves. This intranasal strategy also has the potential to benefit people with weakened immune systems because it does not rely on the person to be able to mount an immune response in order to be protective.
The Company's novel approach has the potential to transform the way the healthcare ecosystem thinks about viral prophylaxis, while also providing an innovative solution for use both in times of seasonal outbreaks as well as pandemic emergencies.
HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats. The €20 million proceeds of this financing will support further development of Leyden Labs' novel, non-vaccine approach to fighting respiratory viruses to contribute to European pandemic preparedness efforts.
Background Information:
Health Emergency Preparedness and Response (HERA). The European Commission's Health Emergency Preparedness and Response Authority (HERA) supports projects that strengthen preparedness and response capacities in the field of health. HERA was established as a direct consequence of the lessons learned from the initial management of the COVID-19 pandemic, to ensure a solid Union response to serious-cross border health threats and secure ready availability and accessibility of medical countermeasures. HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats, and its mandate covers both the strengthening of preparedness in advance of future emergencies and the implementation of a swift and efficient response once crisis hits.
HERA Invest is a €110 million top-up to the InvestEU programme, funded by the EU4Health programme. It is implemented by the EIB and supports projects that focus on pathogens with pandemic potential, chemical, biological, radiological, nuclear threats, and antimicrobial resistance. Together with HERA, the EIB assesses whether an operation meets HERA Invest's criteria.
The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investment for EU policy priorities, such as the European Green Deal and the digital transition. InvestEU brings together under one roof the multitude of EU financial instruments previously available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners who will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.
The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. The Netherlands owns a 5,2% share of the EIB. It makes long-term finance available for sound investment in order to contribute towards EU policy goals and national priorities. More than 90% of its activity is in Europe. Over the last ten years, the EIB has made available more than €27 billion in financing for Dutch projects in various sectors, including research & development, sustainable mobility, drinking water, healthcare and SMEs. In 2024 the EIB Group, which also includes the EIB's subsidiary, the European Investment Fund (EIF), made available more than €3 billion for Dutch projects.
Leyden Laboratories B.V. (Leyden Labs), founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses, by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital / Brook Byers and Bluebird Ventures. To learn more, visit www.leydenlabs.com.
CR9114, Leyden Labs' lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize CR9114.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
13 hours ago
- Forbes
Should We Be Worried About Bird Flu? Public Health Experts Say Yes
Battery hens sit in a chicken shed in Suffolk, England. (Photo by) You don't need me to tell you Covid-19 changed the world. While the pandemic did help expose structural inequalities and disparities, especially in the food system, the loss of life and livelihood has been one of the greatest tragedies of our lifetimes. I'm bringing this up because, if we ignore the lessons we should've learned from this pandemic, future disease outbreaks will be much, much worse. And I'm deeply concerned that, when it comes to avian flu—a.k.a. Highly Pathogenic Avian Influenza A (HPAI) H5N1—we're on a dangerously wrong path. This virus typically affects birds, including poultry, and there's a current outbreak that has affected close to 150 million birds and devastated farms since 2022. Also concerningly, scientists have detected the virus in mammals in recent years—including dairy cows and humans—and learned it can spread between mammals, which significantly raises the outbreak risk. And since 2024, 102 cases of avian flu and 10 deaths have been reported in humans globally, a potentially staggering fatality rate. Many of these global cases over the past year and a half—about 70—have been in the U.S., which means the world's eyes are watching. And so far, this country's response has been nearly the polar opposite of what scientists call for, which puts everyone around the world in greater danger. 'We have so many tools, but they're not being used optimally—and they're not being used optimally by choice,' says Dr. Amesh Adalja, a Senior Scholar at the Johns Hopkins Center for Health Security and an expert in global public health. 'We can change the trajectory of this if we actually take those best practices, take those tools, and use them optimally.' To be perfectly clear, there is currently no known person-to-person spread of avian flu and experts say the current public health risk is low, per the U.S. Centers for Disease Control and Prevention. What this means, though, is that the time to prevent and contain this virus is right now. There's a very real possibility that avian flu could pose a greater threat in the future, and we can't be caught unprepared. The correct course of action involves vaccination, investments in public health, and global collaboration—all of which appear to be under threat given recent U.S. policy developments. Secretary of Agriculture Brooke Rollins' original plan to combat avian flu included US$100 million in research and vaccine development. But shortly after announcing it, she reversed course and told right-wing site Breitbart that vaccines were 'off the table.' Meanwhile, in May, the Trump-Vance Administration cancelled a massive contract with Moderna to develop a vaccination for humans against bird flu, and this month, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the advisory committee that helps develop vaccine policy and recommendations for the CDC. 'I'm optimistic that they will continue to support the development of these vaccines. It would be a crime right now to stop it,' said Scott Hensley, a virologist at the University of Pennsylvania in Philadelphia who worked on an avian flu vaccine for cattle. Vaccines save lives. Just last month, early results from that experimental bird flu vaccine for cattle came back promising. The U.S. Department of Agriculture conditionally approved a vaccine for poultry this spring, and some countries, like China and France, already vaccinate poultry against H5N1. Even in humans, Finland last year became the first country to roll out bird flu vaccines among its population. Alternative courses of action, rather than vaccines, are devastating: In March, Kennedy suggested farmers 'should consider maybe the possibility of letting it run through the flock so that we can identify the birds and preserve the birds that are immune to it.' This, as former Kansas state veterinarian Dr. Gail Hansen put it, is a 'terrible idea' and a 'recipe for disaster.' Dr. Adalja did not mince words. If the past year has been a trial run for how the government might respond to the actual emergence of an avian flu pandemic, he says, 'we've failed this trial run.' Optimistically, on a global level, the World Health Organization (WHO) has been taking positive steps toward international collaboration: WHO's Global Influenza Surveillance and Response System closely monitors avian and other animal influenza viruses, and in May, member states approved an agreement to better prevent, prepare for, and respond to outbreaks and learn from mistakes made at the height of the Covid pandemic. But remember, the Trump-Vance Administration pulled the U.S. out of the WHO effective in 2026, and has revoked a variety of investments in global and domestic health programs. These decisions are not abstract, Dr. Adalja says: they 'make these types of events much harder to prepare for and much harder to control.' As Covid-19 made abundantly clear, viruses don't stop at national borders. Keeping the public healthy and preparing for pandemic risks simply must be more important than politicking. And when we're heading in the wrong direction, there is a moral obligation to sound the alarm—and to illuminate a better path forward.
Yahoo
13 hours ago
- Yahoo
Union presses California's key bird flu testing lab for records
The union representing workers at a UC Davis lab that tests and tracks bird flu infections in livestock has sued the university, demanding that records showing staffing levels and other information about the lab's operations be released to the public. Workers in the lab's small biotechnology department had raised concerns late last year about short staffing and potentially bungled testing procedures as cases of avian flu spread through millions of birds in turkey farms and chicken and egg-laying facilities, as well as through the state's cattle herds. The University Professional and Technical Employees-CWA Local 9119 said that it requested records in December 2024 in an attempt to understand whether the lab was able to properly service the state's agribusiness. But UC Davis has refused to release records, in violation of California's public records laws, the union alleged in a lawsuit recently filed in Alameda County Superior Court. Read more: With bird flu cases on the rise, staff at California lab say they are overworked and burned out UC Davis spokesperson Bill Kisliuk declined to comment on the lawsuit's specific allegations. "The university looks forward to filing our response in court. We are grateful for the outstanding work of the CAHFS lab staff, including UPTE-represented workers, during the 2024 surge in avian flu testing," Kisliuk said in an email. UC Davis has previously denied that workplace issues have left the lab ill-equipped to handle bird flu testing. Kisliuk had said the facility 'maintained the supervision, staffing and resources necessary to provide timely and vital health and safety information to those asking us to perform tests." According to copies of email correspondence cited in the lawsuit, UC Davis in January denied the union's request for records regarding short staffing or testing errors, calling the request "unduly burdensome." It also denied its request for information about farms and other businesses that had samples tested at the lab, citing an exemption to protect from an "invasion of personal privacy." Workers at the lab had previously told The Times that they observed lapses in quality assurance procedures, as well as other mistakes in the testing process. Amy Fletcher, a UC Davis employee and president of the union's Davis chapter, said the records would provide a necessary window into how staffing levels could be hurting farms and other businesses that rely on the lab for testing. Fletcher said workers have become afraid to speak about problems at the lab, having been warned by management that the some information related to testing is confidential. The Davis lab is the only entity in the state with the authority to confirm bird flu cases. The union, known as UPTE, represents about 20,000 researchers and other technical workers across the University of California system's 10 campuses. Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights. This story originally appeared in Los Angeles Times.
Washington Post
a day ago
- Washington Post
Ducks return to a Long Island farm that lost its entire flock to the bird flu
AQUEBOGUE, N.Y. — Doug Corwin knew there was a problem at his family's commercial duck farm in Long Island when he spotted scores of dead or lethargic birds during a barn inspection in January. Within days, Crescent Duck Farm became a casualty of the global avian flu outbreak , one of many farms around the U.S. that had to cull their entire flock, sending the prices of eggs and other agricultural commodities soaring.
